Le Lézard
Classified in: Health, Science and technology
Subject: AWD

Centerline Biomedical honored as Top Surgical Device company for IOPS® navigation and visualization technology


Novel system to mitigate harmful radiation exposure has been deployed in over 200 minimally invasive procedures and featured in documentary film series

CLEVELAND, May 6, 2024 /PRNewswire/ -- Centerline Biomedical, Inc. ("Centerline") has been awarded a MedTech Outlook Award as a 2024 Top Surgical Devices Company. The company is recognized for "Revolutionizing Interventional Procedures with IOPS Technology". Receiving the award, Founder and Chief Technology Officer Vikash Goel stated, "We are thankful to MedTech Outlook for this distinction, but also to our Centerline team for nearly 10 years of tireless work on a technology to protect healers as they perform life-saving procedures and for continuing to develop the platform's reach."

The Intra-Operative Positioning System (IOPS) includes software that creates 3D maps of vascular anatomy, enabling surgeons to visualize the arteries being treated. Using electromagnetic tracking, the IOPS sensor-equipped guidewire and catheter can be guided in 3D as endovascular specialists navigate through these high-resolution intuitive visualizations during minimally invasive procedures. The images and tracking are displayed on an independent monitor, minimizing the reliance on damaging X-ray radiation typically used to produce live fluoroscopic images during interventions. 

"IOPS brings a unique form of 3D visualization, electromagnetic navigation, and radiation safety to endovascular procedures. The idea is to enable increased accuracy and faster procedure times by optimizing what the treating operator can see," said Gulam Khan, Chief Executive Officer of Centerline. "IOPS has been deployed in over 200 procedures at top vascular centers around the USA. Disseminating this technology is critical to the industry goal of decreasing harmful radiation exposure for the patient and clinical staff."

In a new documentary series, Scattered Denial (scattereddenial.org), these dangerous risks are described, and IOPS is presented as a promising technology to mitigate radiation exposure during minimally invasive cardiovascular procedures. 

About Centerline Biomedical

Founded in 2015, Centerline Biomedical is headquartered in Cleveland, Ohio. The company's commercially available platform, Intra-Operative Positioning System, "IOPS®," enables improved visualization and navigation in endovascular procedures. IOPS has 510(k) clearance from the US FDA for use in the descending aorta. The company continues investment in development to enhance the current technology platform and expand image guidance in transcatheter procedure applications.

Visit www.centerlinebiomedical.com for more information.

SOURCE Centerline Biomedical


These press releases may also interest you

at 06:13
eWTP Arabia Capital Technology Fund I ("Techology Fund I"), managed by eWTP Arabia Capital ("eWTPA"), one of the leading private equity firms in the Middle East, was listed in the Preqin League Tables as the the fifth top-performing VC funds in the...

18 mai 2024
Celltrion partners with TV star Mollie Pearce to launch the second installation of the Where's Crohn's & Colitis (CC)? campaign for this year's World IBD Day (19 May 2024). The campaign focuses on access to IBD care and treatment as the burden of...

18 mai 2024
The global industrial automation market in life sciences industry  size is estimated to grow by USD 5.06 bn from 2024-2028, according to Technavio. The market is estimated to grow at a CAGR of  11.4%  during the forecast period. ...

18 mai 2024
"Maximizing customer retention and expansion is more important than ever for B2B SaaS companies," said Steven Forth, CEO of Ibbaka. "Our...

18 mai 2024
Gilead Sciences, Inc. , following the recent acquisition of CymaBay Therapeutics, Inc., today announced interim results from the ongoing ASSURE study demonstrating treatment with seladelpar, an investigational PPAR delta agonist, led to improvements...

18 mai 2024
Mirum Pharmaceuticals, Inc. today announced data presented during the 56th European Society for Paediatric, Gastroenterology, Hepatology, and Nutrition (ESPGHAN) Annual Meeting which took place this week in Milan, Italy. Data from LIVMARLI®...



News published on and distributed by: